Drug Development Groups Life Science 
Healthcare IT Today
MARCH 3, 2025
“Lindus breaks the cycle by completely reinventing the way clinical trials operate, allowing life science companies to iterate faster.” That doesn’t just lead to faster trials, it changes the way companies can think about drug development going from waterfall big bets to agile research.”
Digital Health Global
SEPTEMBER 27, 2023
With these resources, Automera is well positioned to deploy our AUTAC platform toward the development of potentially transformative therapies.” About Automera Automera is an early-stage company focused on the development of a novel therapeutic approach via autophagy-based targeted protein degradation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Digital Health Global
JANUARY 28, 2025
Traditionally, the prudent life sciences industry purchases novel technology incrementally at the study level. Without the economies of scale, this approach often comes with higher service costs. Learn more about what is driving sharp eCOA growth at the annual SCOPE meeting (Feb 3-6, 2025) in Orlando, booth #717.
Digital Health Global
NOVEMBER 20, 2023
With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea, Evinova offers globally-scaled digital products and services to the life sciences and healthcare sector. However, they are vital to the drug development and approval process and critical in enabling access to innovative medicines.
Healthcare IT Today
JANUARY 7, 2025
Chris McSpiritt, Head of Life Sciences at Domino Data Lab Next year will see AI-enhanced imaging technologies significantly improve diagnostic accuracy in radiology and pathology, empowering clinicians to make quicker and more reliable decisions at the point of care. Today, it’s largely restricted to genomics and oncology.
Digital Health Global
MARCH 29, 2023
With ResponderID, we sought to disrupt the historical linear progression of drug discovery and development, rather aiming to close the loop between drug development, patient care and new drug discovery,” said Rafael Rosengarten, Ph.D., co-founder and CEO of Genialis. “We
Digital Health Global
NOVEMBER 30, 2023
Furthermore, by fostering connectivity and automating tasks, DHTs reduce administrative burdens, accelerate recruitment, and improve overall trial transparency, ultimately contributing to faster and more reliable drug development.
Expert insights. Personalized for you.
85 
Let's personalize your content